
WHAT IS CLAIMED IS:

1. Use of a composition comprising a bromodomain inhibitor in the manufacture of a medicament for promoting T-cell activation during cancer immunotherapy, wherein the bromodomain inhibitor in the medicament reduces PD-L1 expression in antigen presenting cells ("APCs").

2. The use of claim 1, wherein bromodomain inhibitor-treated APCs restore responsiveness of anergic CD4+ T cells.

3. The use of claims 1 or 2 , wherein the bromodomain inhibitor is a Bromodomain and extraterminal ("BET") inhibitor.

4. The use of claim 3, wherein the BET inhibitor comprises the following chemical formula: 

.


5. Use of a bromodomain inhibitor and an immunostimulatory agent in the manufacture of a medicament for the treatment of cancer.

6. The use of claim 5, wherein the immunostimulatory agent comprises an anti-PD-1 antibody, an anti-PD-L1 antibody, an anti-CTLA-4 antibody, or a combination thereof.

7. The use of claim 6, wherein the immunostimulatory agent is MPDL3280A.

8. The use of any one of claims 5 to 7, wherein the bromodomain inhibitor is a Bromodomain and extraterminal ("BET") inhibitor.

9. The use of claim 8, wherein the BET inhibitor comprises the following chemical formula:



.

10. The use of any one of claims 5 to 9, wherein the medicament further comprises an immunogenic agent.

11. A method for *ex vivo* activation and expansion of antigen-specific T cells for adoptive cell transfer (ACT), comprising exposing a population of antigen presenting cells (APC) to a population of T lymphocytes in the presence of a bromodomain inhibitor.

12. The method of claim 11, wherein the T lymphocytes are selected from the group consisting of autologous tumor-infiltrating lymphocytes (TIL), T cells transduced with high-affinity T cell receptors (TCR), and T cells transduced with chimeric antigen receptors (CAR).

13. The method of claim 11 or 12, wherein the APCs comprise autologous dendritic cells, macrophages, or a combination thereof.